Weiwei is deeply involved in sustainability, environment, health, safety, data privacy and government regulatory issues in China and the U.S. She advises clients on environmental, health, and safety (EHS) regulatory compliance and supply-chain risk management. She assists clients to identify emerging operational and product issues with a focus on EHS and labor and matters, and to mitigate relevant legal risks. Further, she assists clients in the preparation of EHS audits and government inspections as well as the implementation of remedial actions. She leads B&D’s China EHS roundtable – a forum to help multinational companies in different industries better understand China’s rapidly increasing EHS regulations, manage enforcement risks, and advance EHS compliance, supply chain management, and sustainable development in China.

She also advises clients on chemicals and waste management (including transboundary shipment) and product related issues (e.g., import/export, pre-market assessment, material restrictions, recycling).

Weiwei has been involved in hospital, professional licensing, medicine, medical advertisement, and new technology (including telemedicine) regulatory and investment issues in China.

In the public policy arena, Weiwei routinely monitors and advises on China, U.S., and other legislative and regulatory developments and issues.

Weiwei provides legal assistance to international investors (companies, private equity, institutions) for their various investments in a broad range of industries in China, the U.S., and Europe. She counsels those clients on corporate compliance, mergers and acquisitions, joint ventures and private equity investment, and commercial transactions such as licensing arrangements, distributorships and franchising agreements, as well as other commercial agreements.

Weiwei also advises on international trade issues, working with Chinese and non-U.S. companies and individual investors. Her experience and work in this area focus on pre-market entry and extraterritorially-applied U.S. regulatory programs (e.g., Committee on Foreign Investment in the U.S. (CFIUS), Foreign Corrupt Practices Act (FCPA) and trade sanction matters).